Is early hematopoietic stem-cell transplantation necessary in mantle-cell lymphoma?

Journal of Clinical Oncology

Volumn 32, Issue 4, 2014, Pages 265-267

  Smith, Mitchell R ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BORTEZOMIB; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; IBRUTINIB; KI 67 ANTIGEN; LENALIDOMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE; ANTINEOPLASTIC AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); EDITORIAL; FOLLOW UP; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; REDUCED INTENSITY CONDITIONING; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; MALE; METHODOLOGY; MORTALITY; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; TRANSPLANTATION CONDITIONING;

EID: 84897019006     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.2762     Document Type: Editorial

References (22)

1. Raffeld M, Jaffe ES: Bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 78:259-263, 1991
2. Fenske TS, Zhang M-J, Carreras J, et al: Autologous or reduced-intensity conditioning for allogeneic hematopoietic cell transplantation for chemotherapysensitive mantle-cell lymphoma: Analysis of transplantation timing and modality. J Clin Oncol 32:273-281, 2014
3. Hoster E, Dreyling M, Klapper W, et al: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008
4. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3:185-197, 2003 (Pubitemid 37443390)
5. Determann O, Hoster E, Ott G, et al: Ki-67 predicts outcome in advancedstage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 111:2385-2387, 2008 (Pubitemid 351451450)
6. Budde LE, Guthrie KA, Till BG, et al: Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 29:3023-3029, 2011
7. Geisler CH, Kolstad A, Laurell A, et al: Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur. Br J Haematol 158:355-362, 2012
8. LaCasce AS, Vandergrift JL, Rodriguez MA, et al: Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL Database. Blood 119:2093-2099, 2012
9. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005 (Pubitemid 40450320)
10. Smith MR, Li H, Gordon L, et al: Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 30:3119-3126, 2012
11. Kahl BS, Li H, Smith MR, et al: Mature results from ECOG study E1405: A phase II study of VcR-CVAD with maintenance rituximab for previously untreated mantle cell lymphoma. 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, December 8-11, 2012 (abstr 153)
12. Kluin-Nelemans HC, Hoster E, Hermine O, et al: Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520-531, 2012
13. Hermine O, Hoster E, Walewski J, et al: Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Final analysis of the MCL Younger trial of the European Mantle Cell Lymphoma Network. 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, December 8-11, 2012 (abstr 151)
14. Tam CS, Bassett R, Ledesma C, et al: Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113:4144-4152, 2009
15. Dietrich S, Tielesch B, Rieger M, et al: Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer 117:1901-1910, 2011
16. Liu H, Johnson JL, Koval G, et al: Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: Final results of CALGB 59909. Haematologica 97:579-585, 2012
17. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169, 1986 (Pubitemid 16140378)
18. Ansell SM, Tang H, Kurtin PJ, et al: Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study. Lancet Oncol 12:361-368, 2011
19. Wang M, Fayad L, Wagner-Bartak N, et al: Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial. Lancet Oncol 13:716-723, 2012
20. Wang ML, Rule S, Martin P, et al: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507-516, 2013
21. Rinaldi A, Kwee I, Taborelli M, et al: Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 132:303-316, 2006 (Pubitemid 43381537)
22. Leonard JP, LaCasce AS, Smith MR, et al: Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119:4597-4607, 2012